We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Spot Urine Sample Evaluated for Renal Potassium Loss

By LabMedica International staff writers
Posted on 02 Dec 2020
Hypokalemia is characterized by low serum potassium concentrations. More...
Severe hypokalemia can be life threatening, and immediate potassium replacement is often required to prevent sudden cardiac arrest.

Initial identification of hypokalemia etiology is based on an estimate of urine potassium excretion during a 24-hr urine collection in the absence of potassium supplementation, but the utility of this approach in the emergency department is limited.

Endocrinologists at The Affiliated Hospital of Southwest Medical University (Luzhou, China) divided patients with hypokalemia were into two groups: 67 patients with hypokalemia caused by renal potassium loss and 63 patients with hypokalemia caused by extrarenal potassium loss. Arterial blood gases were measured with an ABL800 blood gas analyzer (Radiometer, Copenhagen, Denmark).

Urine potassium concentration (UK), urine creatinine concentration (UCr), urine potassium-creatinine ratio (UK/UCr), fractional excretion of potassium (FEK), transtubular potassium concentration gradient (TTKG), and 24-h urine potassium excretion (24 hUK-calculated) were derived from spot urine samples collected on admission, and were determined using automated methods on a 7170A automatic biochemistry analyzer (Hitachi Healthcare, Tokyo, Japan).

The scientists reported that patients with hypokalemia caused by renal potassium loss had significantly higher UK, UK/UCr, FEK, TTKG and 24 hUK-calculated compared to patients with hypokalemia caused by extrarenal potassium loss. FEK predicted renal potassium loss in hypokalemia with high accuracy at a cut-off of 9.29% (sensitivity, 80.6%; specificity, 85.7%). Patients with primary aldosteronism had significantly higher UK and TTKG compared to patients without primary aldosteronism. There were no significant differences in UK/UCr, FEK or 24 hUK-calculated between patients with primary aldosteronism and not primary aldosteronism. On the spot urine test, FEK showed the highest correlation with 24 hUK-actual during low or high dose potassium chloride infusion.

The authors concluded that prompt treatment with potassium chloride is required for patients with hypokalemia; 24 hUK-actual is not a suitable marker for predicting renal potassium loss in medical practice. Findings from this study suggest that a spot urine sample collected before potassium chloride therapy has utility for differentiating between renal and extrarenal potassium loss in hypokalemia. FEK from a spot urine sample represents a convenient and reliable parameter to predict renal potassium loss in patients with hypokalemia. The study will be published in the December, 2020 issue of the journal Clinica Chimica Acta.

Related Links:
The Affiliated Hospital of Southwest Medical University
Radiometer
Hitachi Healthcare



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.